サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1417484

血液腫瘍検査市場レポート：2030年までの動向、予測、競合分析

Hemato Oncology Testing Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日: | 発行: Lucintel | ページ情報: 英文 150 - page report | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

血液腫瘍検査市場レポート：2030年までの動向、予測、競合分析
出版日: 2024年01月29日
発行: Lucintel
ページ情報: 英文 150 - page report
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

血液腫瘍検査の動向と予測

世界の血液腫瘍検査市場は、2024年から2030年までのCAGRが14.5%で、2030年までに推定72億米ドルに達すると予想されます。この市場の主な促進要因は、個別化医療に関する学会数の増加、血液がん罹患率の上昇、民間診断施設の増加です。世界の血液腫瘍検査市場の将来は、病院および学術・研究機関市場の機会によって有望視されています。

血液腫瘍検査市場の洞察

Lucintelの予測では、オーダーメイドの薬物療法を含むさまざまな治療オプションに関する一般知識の増加により、予測期間中もサービスがより大きなセグメントであり続ける。

北米は、多発性骨髄腫、リンパ腫、白血病の有病率の増加、最先端の医療施設やヘルスケアの利用可能性、新技術の導入により、予測期間中も最大地域であり続けると思われます。

よくある質問

Q1.市場規模は？

A1.世界の血液腫瘍検査市場は、2030年までに推定72億米ドルに達すると予想されています。

Q2.市場の成長予測は？

A2.世界の血液腫瘍検査市場は、2024年から2030年にかけてCAGR 14.5%で成長すると予想されます。

Q3.市場の成長に影響を与える主な促進要因は？

A3.この市場の主な促進要因は、個別化医療に関する学会数の増加、血液がん罹患率の上昇、民間診断施設の増加です。

Q4.市場の主要セグメントは？

A4.世界の血液腫瘍検査市場の将来は、病院、学術と研究機関市場の機会により有望です。

Q5.市場の主要企業は？

A5.主要な血液腫瘍検査企業は以下の通りです。

  • F. Hoffmann-La Roche
  • Abbott
  • EntroGen
  • Qiagen
  • Cepheid
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Illumina
  • Amoy Diagnostics
  • ArcherDX

Q6.今後、最大となる市場セグメントは？

A6.Lucintelは、オーダーメイドの薬物療法を含む様々な治療オプションに関する一般的な知識の増加により、予測期間中はサービスがより大きなセグメントであり続けると予測しています。

Q7.市場において、今後5年間に最大になると予想される地域は？

A7.北米は、多発性骨髄腫、リンパ腫、白血病の有病率の増加、最先端の医療施設やヘルスケアの利用可能性、新技術のイントロダクションより、予測期間中も最大地域であり続ける。

Q8.レポートのカスタマイズは可能？

A8.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界の血液腫瘍検査市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界の血液腫瘍検査市場動向（2018-2023）と予測（2024-2030）
  • 技術別の世界の血液腫瘍検査市場
    • PCR
    • IHC
    • NGS
    • 細胞遺伝学
    • その他
  • がんの種類別の世界の血液腫瘍検査市場
    • 白血病
    • リンパ腫
    • 骨髄増殖性腫瘍
    • その他
  • 製品別の世界の血液腫瘍検査市場
    • アッセイキットと試薬
    • サービス
  • 最終用途別の世界の血液腫瘍検査市場
    • 病院
    • 学術調査機関
    • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界の血液腫瘍検査市場
  • 北米の血液腫瘍検査市場
  • 欧州の血液腫瘍検査市場
  • アジア太平洋の血液腫瘍検査市場
  • その他地域の血液腫瘍検査市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • 技術による世界の血液腫瘍検査市場の成長機会
    • がんの種類別の世界の血液腫瘍検査市場の成長機会
    • 製品別の世界の血液腫瘍検査市場の成長機会
    • 最終用途別の世界の血液腫瘍検査市場の成長機会
    • 地域別の世界の血液腫瘍検査市場の成長機会
  • 世界の血液腫瘍検査市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界の血液腫瘍検査市場の能力拡大
    • 世界の血液腫瘍検査市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • F. Hoffmann-La Roche
  • Abbott
  • EntroGen
  • Qiagen
  • Cepheid
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Illumina
  • Amoy Diagnostics
  • ArcherDX
目次

Hemato Oncology Testing Trends and Forecast

The future of the global hemato oncology testing market looks promising with opportunities in the hospital and academic & research institutes market. The global hemato oncology testing market is expected to reach an estimated $7.2 billion by 2030 with a CAGR of 14.5% from 2024 to 2030. The major drivers for this market are increasing the number of conferences on personalized medicine, rising rate of hematologic cancer, and growing number of privately run diagnostic facilities.

A more than 150-page report is developed to help in your business decisions.

Hemato Oncology Testing by Segment

The study includes a forecast for the global hemato oncology testing by technology, cancer type, product, end use, and region.

Hemato Oncology Testing Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

  • PCR
  • IHC
  • NGS
  • Cytogenetics
  • Others

Hemato Oncology Testing Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

  • Leukemia
  • Lymphoma
  • Myeloproliferative Neoplasms
  • Other

Hemato Oncology Testing Market by Product [Shipment Analysis by Value from 2018 to 2030]:

  • Assay Kits and Reagents
  • Services

Hemato Oncology Testing Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Academic & Research Institutes
  • Others

Hemato Oncology Testing Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Hemato Oncology Testing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies hemato oncology testing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the hemato oncology testing companies profiled in this report include-

  • F. Hoffmann-La Roche
  • Abbott
  • EntroGen
  • Qiagen
  • Cepheid
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Illumina
  • Amoy Diagnostics
  • ArcherDX

Hemato Oncology Testing Market Insights

Lucintel forecasts that service will remain the larger segment over the forecast period due to increasing public knowledge of various treatment options, including tailored medications.

North America will remain the largest region over the forecast period due to the increased prevalence of multiple myeloma, lymphoma, and leukemia, along with the availability of cutting-edge medical facilities and healthcare, as well as the introduction of new technology.

Features of the Global Hemato Oncology Testing Market

Market Size Estimates: Hemato oncology testing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Hemato oncology testing market size by various segments, such as by technology, cancer type, product, end use, and region in terms of value ($B).

Regional Analysis: Hemato oncology testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different technology, cancer type, product, end use, and regions for the hemato oncology testing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the hemato oncology testing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the hemato oncology testing market size?

Answer: The global hemato oncology testing market is expected to reach an estimated $7.2 billion by 2030.

Q2. What is the growth forecast for hemato oncology testing market?

Answer: The global hemato oncology testing market is expected to grow with a CAGR of 14.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the hemato oncology testing market?

Answer: The major drivers for this market are increasing the number of conferences on personalized medicine, rising rate of hematologic cancer, and growing number of privately run diagnostic facilities.

Q4. What are the major segments for hemato oncology testing market?

Answer: The future of the global hemato oncology testing market looks promising with opportunities in the hospital and academic & research institutes market.

Q5. Who are the key hemato oncology testing market companies?

Answer: Some of the key hemato oncology testing companies are as follows.

  • F. Hoffmann-La Roche
  • Abbott
  • EntroGen
  • Qiagen
  • Cepheid
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Illumina
  • Amoy Diagnostics
  • ArcherDX

Q6. Which hemato oncology testing market segment will be the largest in future?

Answer: Lucintel forecasts that service will remain the larger segment over the forecast period due to increasing public knowledge of various treatment options, including tailored medications.

Q7. In hemato oncology testing market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to the increased prevalence of multiple myeloma, lymphoma, and leukemia, along with the availability of cutting-edge medical facilities and healthcare, as well as the introduction of new technology.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the hemato oncology testing market by technology (PCR, IHC, NGS, cytogenetics, and others), cancer type (leukemia, lymphoma, myeloproliferative neoplasms, and other), product (assay kits and reagents and services), end use (hospitals, academic & research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Hemato Oncology Testing Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Hemato Oncology Testing Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Hemato Oncology Testing Market by Technology
    • 3.3.1: PCR
    • 3.3.2: IHC
    • 3.3.3: NGS
    • 3.3.4: Cytogenetics
    • 3.3.5: Others
  • 3.4: Global Hemato Oncology Testing Market by Cancer Type
    • 3.4.1: Leukemia
    • 3.4.2: Lymphoma
    • 3.4.3: Myeloproliferative Neoplasms
    • 3.4.4: Other
  • 3.5: Global Hemato Oncology Testing Market by Product
    • 3.5.1: Assay Kits and Reagents
    • 3.5.2: Services
  • 3.6: Global Hemato Oncology Testing Market by End Use
    • 3.6.1: Hospitals
    • 3.6.2: Academic & Research Institutes
    • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Hemato Oncology Testing Market by Region
  • 4.2: North American Hemato Oncology Testing Market
    • 4.2.1: North American Hemato Oncology Testing Market by Product: Assay Kits and Reagents and Services
    • 4.2.2: North American Hemato Oncology Testing Market by End Use: Hospitals, Academic & Research Institutes, and Others
  • 4.3: European Hemato Oncology Testing Market
    • 4.3.1: European Hemato Oncology Testing Market by Product: Assay Kits and Reagents and Services
    • 4.3.2: European Hemato Oncology Testing Market by End Use: Hospitals, Academic & Research Institutes, and Others
  • 4.4: APAC Hemato Oncology Testing Market
    • 4.4.1: APAC Hemato Oncology Testing Market by Product: Assay Kits and Reagents and Services
    • 4.4.2: APAC Hemato Oncology Testing Market by End Use: Hospitals, Academic & Research Institutes, and Others
  • 4.5: ROW Hemato Oncology Testing Market
    • 4.5.1: ROW Hemato Oncology Testing Market by Product: Assay Kits and Reagents and Services
    • 4.5.2: ROW Hemato Oncology Testing Market by End Use: Hospitals, Academic & Research Institutes, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Hemato Oncology Testing Market by Technology
    • 6.1.2: Growth Opportunities for the Global Hemato Oncology Testing Market by Cancer Type
    • 6.1.3: Growth Opportunities for the Global Hemato Oncology Testing Market by Product
    • 6.1.4: Growth Opportunities for the Global Hemato Oncology Testing Market by End Use
    • 6.1.5: Growth Opportunities for the Global Hemato Oncology Testing Market by Region
  • 6.2: Emerging Trends in the Global Hemato Oncology Testing Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Hemato Oncology Testing Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Hemato Oncology Testing Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: F. Hoffmann-La Roche
  • 7.2: Abbott
  • 7.3: EntroGen
  • 7.4: Qiagen
  • 7.5: Cepheid
  • 7.6: Thermo Fisher Scientific
  • 7.7: Bio-Rad Laboratories
  • 7.8: Illumina
  • 7.9: Amoy Diagnostics
  • 7.10: ArcherDX